Q-omics provides the consensus-scored RN7SKP9 profile across patient tissues and cancer cell-line models. RN7SKP9 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, RN7SKP9 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, RN7SKP9 RNA expression shows 7,208 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, LUSC, and LSCC as cancer lineages where RN7SKP9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP9 survival associations across molecular data types. RN7SKP9 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP9 RNA expression–survival associations across cancer types. High RN7SKP9 expression shows unfavorable associations in TGCT, UVM, OV and CESC, but favorable associations in PAAD and COAD. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for RN7SKP9 RNA expression.
This table summarizes RN7SKP9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP9 shows lower tumor expression in THCA and higher tumor expression in LUSC, HNSC, BLCA and COAD. The LUSC box plot shows higher RN7SKP9 RNA expression in tumor versus normal tissue (log2 FC = +0.118, t-test p = .007).
This table shows molecular features associated with RN7SKP9 in patient tissues and cancer cell lines. In patient samples, RN7SKP9 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
